Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
about
Perampanel inhibition of AMPA receptor currents in cultured hippocampal neuronsEpilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewPerampanelPerampanel for focal epilepsy: insights from early clinical experiencePerampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptabilityReview of clinical studies of perampanel in adolescent patientsClinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizuresMechanisms of Action of Antiseizure Drugs and the Ketogenic DietEfficacy of perampanel: a review of pooled data.Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.DRESS associated with perampanel administration in a child with drug-resistant epilepsy.Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience.Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.Time to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpointPerampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizuresPsychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side EffectsImpact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials.Perampanel (Fycompa): A Review of Clinical Efficacy and Safety in Epilepsy.New developments in the management of partial-onset epilepsy: role of brivaracetam.BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy.Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures.The discovery and development of perampanel for the treatment of epilepsy.Perampanel: A Review in Drug-Resistant Epilepsy.Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy.Current role of perampanel in pediatric epilepsy.New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center.Effect of adjunctive perampanel on the quality of sleep and daytime somnolence in patients with epilepsy.Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease).Perampanel: a selective AMPA antagonist for treating seizures.Add-on perampanel in Lance-Adams syndrome.Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel.Efficacy of perampanel in a patient with epilepsia partialis continua.Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
P2860
Q21131943-6784FA02-45EC-4ABC-8F41-A7E871B6EB75Q26743786-F71A1C32-A73E-48ED-9154-A9BAEF4D4BD4Q26773308-83B21B36-2673-49A9-B855-9A965E5DA0CAQ26778392-4D40FE54-0B1C-4583-8EEC-E6EA4207AA26Q26796447-007A077A-7AE2-499A-89F0-27FBECC1E18EQ28077432-8AC9BEC6-393B-442C-85D5-BF7B05F3EB02Q28078666-C4EA6639-887A-4972-9FCB-559BEF65F4D2Q28272457-2E075574-1EF6-423E-8575-41B648F6686DQ30728243-18F54023-6426-4CF5-A115-0A1501039E94Q31140311-4CCB80F9-6BFE-4894-83C4-FF0357F4B8F4Q34771205-6CC80048-FB27-4471-B485-2471AC37FF58Q34823061-776AD769-981C-4489-9B55-279CE147CE3EQ35537344-B236FCB7-C5C7-496E-9F4D-FB7863EA06CEQ35611628-F514C31F-C7D3-4085-BB71-7F8C4E80AD99Q35639962-304656E2-974A-487E-8A75-A0C5AE710E54Q36052924-D0C42A5C-4266-4C4D-AC19-92ADE6E89185Q36554228-BCC9C223-E2E8-43BD-B45C-24A2831D6065Q36592836-E6104CB7-F666-4002-B70C-22A3F2889EE1Q37021062-4D765993-237A-45E6-9E46-AAEE07FF12DFQ37149455-A6061DF3-AD21-444C-BBD0-A6E844C04E1DQ37372197-D54BDFE8-4586-48B2-A33D-BC220B80A8C1Q37693757-B443F0AD-4164-4E3F-9C35-125A77CF3328Q38154633-F4D6C965-7F6B-4600-A230-88819A1C30ADQ38179459-B28F8EBF-B880-4A89-89D0-2F2448F884F4Q38190084-2D943A35-0B0A-41C8-B4D7-6879DAFDF938Q38586792-67C60341-3895-4460-A49C-EC12BE50E3E2Q38599106-0D6EE75D-BA3A-4526-AEB4-93D5D3C1B76BQ38617833-1CCDF2EF-B22B-40E1-9702-42CC82B4D7ABQ38675314-963F09EB-2F32-4A6A-AB98-B366D1819D6BQ38851234-221DF94A-3E83-498C-8C07-B19DFAB2BA79Q39094490-C81E4D82-69B7-443C-A8C9-1A14ABEE1D8DQ39311787-E18A72E3-C498-4598-A0AA-5A8FC064E0BBQ40345208-964AB0A4-FF97-4C36-9FED-0B5DF0EE3805Q41455462-815E8447-4833-42E2-811C-6350520E485BQ41873465-D95AFF44-9F11-46C9-A65E-4CD675D5FD69Q42426744-89F8D74B-C003-4DD8-B53A-E312D012EBB9Q42647249-26CC4954-5328-4A24-93BC-F614304BA126Q43120633-EA3B85E5-99D6-4FE9-9363-BF8072F21577Q47101524-6AC31694-95BE-4556-8283-BF07D3EDA953Q47293306-EC98D1D1-7B3B-4338-9581-01B5E261557E
P2860
Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Efficacy and safety of adjunct ...... is of three phase III studies.
@en
type
label
Efficacy and safety of adjunct ...... is of three phase III studies.
@en
prefLabel
Efficacy and safety of adjunct ...... is of three phase III studies.
@en
P2093
P2860
P356
P1433
P1476
Efficacy and safety of adjunct ...... sis of three phase III studies
@en
P2093
Andrew Satlin
Antonio Laurenza
Bernhard J Steinhoff
David Squillacote
Elinor Ben-Menachem
Haichen Yang
Lynn Kramer
P2860
P304
P356
10.1111/EPI.12212
P577
2013-05-10T00:00:00Z